Pcn90 - Cost-Effectiveness and Budget Impact Analysis of Nilotinib for the Second Line Tratment of Chronic Mieloid Leukemia in the Russian Federation

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.172
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV


Related search